PT - JOURNAL ARTICLE AU - Servellita, Venice AU - Gonzalez, Alicia Sotomayor AU - Lamson, Daryl M. AU - Foresythe, Abiodun AU - Huh, Hee Jae AU - Bazinet, Adam L. AU - Bergman, Nicholas H. AU - Bull, Robert L. AU - Garcia, Karla Y. AU - Goodrich, Jennifer S. AU - Lovett, Sean P. AU - Parker, Kisha AU - Radune, Diana AU - Hatada, April AU - Pan, Chao-Yang AU - Rizzo, Kyle AU - Bertumen, J Bradford AU - Morales, Christina AU - Oluniyi, Paul E. AU - Nguyen, Jenny AU - Tan, Jessica AU - Stryke, Doug AU - Jaber, Rayah AU - Leslie, Matthew T. AU - Lyons, Zin AU - Hedman, Hayden AU - Parashar, Umesh AU - Sullivan, Maureen AU - Wroblewski, Kelly AU - Oberste, M. Steven AU - Tate, Jacqueline E. AU - Baker, Julia M. AU - Sugerman, David AU - Potts, Caelin AU - Lu, Xiaoyan AU - Chhabra, Preeti AU - , AU - Ingram, L. Amanda AU - Shiau, Henry AU - Britt, William AU - Gutierrez Sanchez, Luz Helena AU - Ciric, Caroline AU - Rostad, Christina A. AU - Vinjé, Jan AU - Kirking, Hannah L. AU - Wadford, Debra A. AU - Raborn, R. Taylor AU - George, Kirsten St. AU - Chiu, Charles Y. TI - Adeno-associated virus type 2 in children from the United States with acute severe hepatitis AID - 10.1101/2022.09.19.22279829 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.19.22279829 4099 - http://medrxiv.org/content/early/2022/09/21/2022.09.19.22279829.short 4100 - http://medrxiv.org/content/early/2022/09/21/2022.09.19.22279829.full AB - As of August 2022, cases of acute severe hepatitis of unknown etiology in children have been reported from 35 countries, including the United States. Here we used PCR testing, viral enrichment based sequencing, and agnostic metagenomic sequencing to analyze 27 samples, including nasopharyngeal swab, stool, plasma, and/or whole blood, from 16 such cases from 6 states (Alabama, California, Florida, Illinois, North Carolina, and South Dakota) presenting from October 1, 2021 to May 22, 2022, in parallel with whole blood samples from 45 controls. Among the 13 cases for whom whole blood was available, adeno-associated virus 2 (AAV2) sequences were detected in 92% (12 of 13) (p<0.001), while adenovirus sequences were detected in 100%, of which 11 (84.6%) were genotyped as human adenovirus type 41 (HAdV-41), one as HAdV-40, and one as HAdV-2. Co-infections of herpesviruses, Epstein-Barr virus (EBV) or human herpesvirus 6 (HHV-6), and/or enterovirus A71 (EV-A71) were also detected in all 13 cases. In contrast, AAV2 and HAdV-41 were not detected in any control, and EBV, HHV-6, or EV-A71 were each only detected in one or two of 45 controls (p<0.001). Analysis of assembled AAV2 viral genome sequences identified 35 coding mutations relative to the AAV2 reference genome, predominantly located in the VP1 capsid and assembly-activating protein (AAP) proteins, and AAV2 genomes from cases clustered together by phylogenetic analysis. Our findings of a distinct AAV2 strain in nearly all cases of acute severe hepatitis of unknown etiology in conjunction with one or more infecting helper viruses suggest that disease pathogenesis and/or severity may be related to co-infection with AAV2.Competing Interest StatementC.Y.C. is a founder of Delve Bio and on the scientific advisory board for Delve Bio, Mammoth Biosciences, BiomeSense, and Poppy Health. He is also a co-inventor on U.S. patent 11380421, Pathogen Detection using Next Generation Sequencing, under which algorithms for taxonomic classification, filtering, and pathogen detection are used by SURPI+ software. C.A.R. has received funds to conduct clinical research unrelated to this manuscript from BioFire Inc, GSK, Janssen, MedImmune, Merck, Moderna, Novavax, PaxVax, Pfizer, Regeneron, Sanofi-Pasteur. She is co-inventor of patented RSV vaccine technology, which has been licensed to Meissa Vaccines, Inc. KSG receives research support unrelated to this manuscript from ThermoFisher and has a royalty generating collaborative agreement with Zeptometrix. The other authors declare no competing interests.Funding Statementlibraries on short notice from the samples they were provided. This work was funded in part by US Centers for Disease Control and Prevention contracts 75D30121C12641 and 75D30121C10991 (C.Y.C.), BARDA contract 75A50122C00022, and National Institutes of Health (NIH)/National Institute of Child Health and Human Development (NICHD) grant R61HD105618 (C.Y.C. and C.A.R.). This work was also funded in part under Agreement No. HSHQDC-15-C-00064 awarded to Battelle National Biodefense Institute (BNBI) by the Department of Homeland Security (DHS), Science and Technology Directorate (S&T), for the management and operation of the National Biodefense Analysis and Countermeasures Center (NBACC), a Federally Funded Research and Development Center. This manuscript has been authored in part by Battelle National Biodefense Institute, LLC under contract with DHS. The publisher, by accepting the article for publication, acknowledges that the United States Government retains a non-exclusive, paid up, irrevocable, world-wide license to publish or reproduce the published form of this manuscript, or allow others to do so, for United States Government purposes. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Remnant clinical samples from cases with acute severe hepatitis were collected and analyzed under no subject contact protocols with waiver of informed consent approved by the institutional review boards (IRBs) of University of Alabama, Birmingham, California Department of Public Health, New York State Department of Health, and CDC. Whole blood samples from pediatric controls (age < 18) from Childrens Healthcare of Atlanta were prospectively collected and analyzed under a protocol approved by the Emory IRB (STUDY00000723); parents or guardians of these children provided oral consent for study enrollment and collection and analysis of their samples. Remnant whole blood samples from pediatric controls (age < 18) at University of California, San Francisco (UCSF) were collected, biobanked, and analyzed under a no subject contact protocol with waiver of informed consent approved by the UCSF IRB (protocol no. 11-05519). This investigation was reviewed by CDC and conducted consistent with applicable federal law and CDC policy (45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.